Economic Evaluation of Comprehensive Genomic Profiling in an Advanced Solid Cancer Population
This economic evaluation of CGP in patients with advanced cancer estimated the diagnostic cost to match a treatment. CGP-matched treatment cost and benefit requirements were estimated under which CGP was cost-effective, thereby providing health care decision-makers with relevant economic evidence for decision-making.
Authors
- Hedwig M. Blommestein (ORCID: https://orcid.org/0000-0002-5846-0531)
- Brigitte Maes (ORCID: https://orcid.org/0009-0004-2301-3370)
- Guy Froyen (ORCID: https://orcid.org/0000-0002-6671-1572)
- Wim H. van Harten (ORCID: https://orcid.org/0000-0001-9580-0489)
- Philippe Aftimos (ORCID: https://orcid.org/0000-0001-9946-4726)
- Evandro de Azambuja (ORCID: https://orcid.org/0000-0001-9501-4509)
- Pieter‐Jan Volders (ORCID: https://orcid.org/0000-0002-2685-2637)
- Valesca P. Retèl (ORCID: https://orcid.org/0000-0002-5624-3234)
- Lucas F. van Schaik
Institutions
- Université Libre de Bruxelles (BE)
- Institut Jules Bordet (BE)
- The Netherlands Cancer Institute (NL)
- Jessa Hospital (BE)
- Hasselt University (BE)
- Erasmus University Rotterdam (NL)
- University of Twente (NL)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.48538
- Citations
- 1
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.82